Iconovo develops new inhalation drugs in collaboration with international pharmaceutical companies. The development projects are based on the company's inhaler platforms ICOres, ICOcap, ICOone and ICOpre.
Feasibility study with binding protein
Iconovo recently announced that they plan to launch a feasibility study in collaboration with Affilogic for the development of inhalable Nanofitin-based biotherapies in ICOone.
Affilogic is a private biotechnology company specializing in the discovery and development of Nanofitins, which is the commercial name for so-called affitins. These are artificial proteins that bind to specific antigens and thus constitute an alternative to antibodies.
Possibility of licensing agreements
The ambition of Affilogic's project is to develop a new Nanofitin-based inhalation treatment for lung diseases.
Following completion of the feasibility study, Affilogic has the option to enter into a licensing agreement with Iconovo for use of the treatment in one of the company's ICOone inhalers. A potential licensing agreement could generate revenue through development work, milestone and royalty payments, or sales of inhalers.
Several cooperation agreements
Earlier in June, Iconovo also entered into a similar collaboration agreement with a smaller Danish company. This is also a feasibility study that, if successful, could generate a licensing agreement for Iconovo. The project concerns the development of a reformulated version of an already approved drug substance for a rare inflammatory disease that often affects the lungs.
Iconovo CEO Johan Waborg commented to BioStock regarding the recent influx of collaboration agreements:
»The fact that more and more customers are choosing Iconovo as a partner is a testament to our expertise in the inhalation area. We have made a number of deals in the area of original pharmaceuticals recently, which is not only good from a business perspective, but also gives us an opportunity to develop our expertise with new substances and methods. The customer project with Affilogic in particular can generate significant knowledge about the development of biological medicines – a growing market with great potential for our inhalers.«
